Sonya Zabludoff - Concepedia

Author

Sonya Zabludoff

Also Known As

S D Zabludoff, S Zabludoff, S. Zabludoff, S.D. Zabludoff, SONYA D. ZABLUDOFF, Sonya D Zabludoff, Sonya D. Zabludoff, Sonya Zabludoff

130

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Johns Hopkins University Regulus Therapeutics (United States)AstraZeneca (United Kingdom)University of Michigan

About

Sonya Zabludoff is an author at AstraZeneca (United States) specializing in medicine, tumor biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	2.1K
2	Natural Sciences	6	6	303
3	Engineering	2	2	64
4	Public Health	2	2	84
5	Social Sciences	2	2	89

Sonya Zabludoff

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Andrew L. Kung, Sonya Zabludoff, Dennis S. France, Cancer Cell Transcriptional CoactivationTranscriptional RegulationRedox RegulatorHypoxia (Medicine)Gene Expression	2004	474
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Sonya Zabludoff, Chun Deng, Michael Grondine, Molecular Cancer Therapeutics Cell DeathCell CycleCancer BiologyTumor BiologyOncology	2008	407
Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects Lidia Sambucetti, Denise Fischer, Sonya Zabludoff, Journal of Biological Chemistry	1999	392
Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair Meredith A. Morgan, Leslie A. Parsels, Lili Zhao, Cancer Research Dna DamageMedian TimeMolecular BiologyPathologyTumor Biology	2010	296
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors Edward A. Sausville, Patricia LoRusso, Michael A. Carducci, Cancer Chemotherapy and Pharmacology Checkpoint Kinase InhibitorMedicinePathologyAdvanced Solid TumorsImmune Checkpoint Inhibitor	2014	195
Proteomics-based Target Identification Harry Towbin, Kenneth W. Bair, James A. DeCaprio, Journal of Biological Chemistry	2003	144
<i>In vitro</i> and <i>In vivo</i> Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762 James B. Mitchell, Rajani Choudhuri, Kristin Fabre, Clinical Cancer Research	2010	128
Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening Paul D. Lyne, Peter W. Kenny, David A. Cosgrove, Journal of Medicinal Chemistry Drug TargetHit IdentificationMolecular BiologyTumor BiologyMedicinal Chemistry	2004	111
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase Samuel McNeely, Chiara Conti, Tahir Sheikh, Cell Cycle	2010	98
miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells Jing Zhang, Jingjing Jiao, Silvia Cermelli, Cancer Research PathologyCell DeathCholangiopathiesCancer BiologyTumor Biology	2015	95

Page 1